Literature DB >> 11306144

Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells.

M Kornacker1, M R Verneris, B Kornacker, C Scheffold, R S Negrin.   

Abstract

The prevention of apoptosis may be critical for immunological function. Survivin is a recently cloned member of the inhibitor of apoptosis protein family. We analyzed survivin expression before and after lymphocyte activation in isolated cell populations. Prior to activation, survivin was undetectable. After activation with IL-2 and OKT-3, CD3(+) cells expressed survivin. Next, we correlated survivin expression with Fas, FasL and the amount of apoptosis over time in culture. After activation, survivin was readily detected by day 2 and decreased thereafter. Prior to activation (day 0), Fas was present on 60% of the cells and on 100% by days 2-6. Peak FasL mRNA expression was at day 2. During peak survivin expression (days 2-4) the apoptotic fraction was low, but when survivin expression decreased the apoptotic fraction increased rapidly. Finally, we found that CD45RO(+) memory T cells showed a higher expression of survivin than did CD45RA(+) naive T cells after activation. These results suggest that survivin may contribute to T-cell survival early in T-cell responses as well as in memory immune responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306144     DOI: 10.1016/s0165-2478(01)00186-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  16 in total

Review 1.  Role of the Survivin gene in pathophysiology.

Authors:  Fengzhi Li; Michael G Brattain
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  Apoptosis prediction via inhibition of AKT signaling pathway by neogrifolin.

Authors:  Yang Chen; Guo-Fang Peng; Xiang-Zhen Han; Wei Wang; Guo-Qiang Zhang; Xiao Li
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease.

Authors:  Heitor S P de Souza; Gail A West; Nancy Rebert; Carol de la Motte; Judy Drazba; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2012-06-26       Impact factor: 22.682

4.  Inhibition of caspase-3 by Survivin prevents Wee1 Kinase degradation and promotes cell survival by maintaining phosphorylation of p34Cdc2.

Authors:  Javier Rivera Guzman; Seiji Fukuda; Louis M Pelus
Journal:  Gene Ther Mol Biol       Date:  2009

5.  Survivin-specific T cell receptor targets tumor but not T cells.

Authors:  Caroline Arber; Xiang Feng; Harshal Abhyankar; Errika Romero; Meng-Fen Wu; Helen E Heslop; Patrick Barth; Gianpietro Dotti; Barbara Savoldo
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

6.  [Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes: an in vitro study].

Authors:  P Niemeyer; A Seckinger; H G Simank; P Kasten; N Südkamp; U Krause
Journal:  Orthopade       Date:  2004-12       Impact factor: 1.087

7.  IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.

Authors:  Mary Zimmerman; Dafeng Yang; Xiaolin Hu; Feiyan Liu; Nagendra Singh; Darren Browning; Vadivel Ganapathy; Phillip Chandler; Divaker Choubey; Scott I Abrams; Kebin Liu
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

8.  Bifunctional roles of survivin-ΔEx3 and survivin-2B for susceptibility to apoptosis in endometrial carcinomas.

Authors:  Yuki Tazo; Atsuko Hara; Takashi Onda; Makoto Saegusa
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-12       Impact factor: 4.553

9.  Lymphocyte apoptosis in murine Pneumocystis pneumonia.

Authors:  Xin Shi; Nicole J LeCapitaine; Xiaowen L Rudner; Sanbao Ruan; Judd E Shellito
Journal:  Respir Res       Date:  2009-06-26

10.  Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis.

Authors:  Sofia E M Andersson; Mattias N D Svensson; Malin C Erlandsson; Mats Dehlin; Karin M E Andersson; Maria I Bokarewa
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.